Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST StudyPaola Guglielmelli, Tiziano Barbui, Arianna Ghirardi et al.|Blood Advances|2021Cited by 66
Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosisHelna Pettersson, Björn Andréasson, Håvar Knutsen et al.|European Journal Of Haematology|2014Cited by 39
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS scoreTiziano Barbui, Alessandro M. Vannucchi, Arianna Masciulli et al.|Blood Cancer Journal|2022Cited by 14
Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐upErik Ahlstrand, Björn Andréasson, Jan Samuelsson et al.|European Journal Of Haematology|2019Cited by 13
<i>ASXL1</i> mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patientsBjörn Andréasson, Julia Asp, Helna Pettersson et al.|British Journal of Haematology|2020Cited by 12